Anzeige
Mehr »
Sonntag, 12.07.2026 - Börsentäglich über 12.000 News
Kanadas U-Boot-Milliarden zünden den nächsten Wolfram-Boom: Dieser US-Nanocap sitzt an der Quelle
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 859034 | ISIN: US1266501006 | Ticker-Symbol: CVS
Tradegate
10.07.26 | 17:39
91,92 Euro
+0,72 % +0,66
1-Jahres-Chart
CVS HEALTH CORPORATION Chart 1 Jahr
5-Tage-Chart
CVS HEALTH CORPORATION 5-Tage-Chart
RealtimeGeldBriefZeit
91,0491,4217:52
91,1491,4010.07.
ACCESS Newswire
797 Leser
Artikel bewerten:
(2)

CVS Health Recognized for Technology That Improves Medication Safety and Patient Care

NORTHAMPTON, MA AND WOONSOCKET, RI / ACCESS Newswire / June 9, 2026 / CVS Health

The company was awarded a 2026 Newsweek AI Impact Award

Originally published on CVS Health Company Newsroom

CVS Health (NYSE:CVS) announced it has been recognized by Newsweek with the 2026 AI Impact Award in the AI Health Care category, specifically for Best Outcomes - Patient Care. The award recognizes CVS Health's AI-Driven Prescription Interpretation and Instruction Standardization technology, which embeds artificial intelligence directly into pharmacy dispensing workflows to help pharmacists improve medication safety and patient care across the company's national pharmacy network.

"This recognition reflects our commitment to applying AI in ways that ultimately free up our clinicians' time to better serve patients," said Tony Ambrozie, Senior Vice President and Chief Digital and Technology Officer at CVS Health. "By embedding intelligent automation into our pharmacy workflows, we're giving our pharmacists and technicians more time to focus on what they do best: providing expert clinical support to the patients who depend on us. This is what responsible, patient-centric AI looks like in practice."

The Newsweek AI Impact Awards spotlight practitioner-led AI solutions delivering measurable, real-world impact. Award winners are featured on Newsweek.com.

Transforming prescription processing through responsible AI

Across the U.S. health care system, pharmacies routinely receive electronic prescriptions containing complex directions for use. These instructions historically required manual transcription by pharmacy teams, creating administrative burden and limiting the time clinicians could dedicate to direct patient support.

CVS Health addressed this challenge by deploying trained open-source large language models (LLMs) to interpret prescriber directions, parsing clinical terminology, conditional dosing logic, and contextual nuance that legacy rules-based systems could not process. In parallel, AI-driven logic analyzes frequency, quantity, and duration fields to calculate precise dosage supply - one of the most labor-intensive steps in prescription processing.

Delivering results across retail and specialty pharmacy

The solution has delivered significant, measurable outcomes across both retail and specialty pharmacy settings:

In retail pharmacy, automating this repetitive task accelerates prescription fulfillment and reduces delays at the point of care, with operational gains directly reallocated to expand clinical support capabilities.

In specialty pharmacy, where patients often manage chronic, rare, or life-threatening conditions, this tool has helped CVS Specialty onboard patients and fill their prescriptions more quickly, so they can begin therapy faster.

Patient safety and responsible AI deployment were foundational design principles throughout development. Model performance is continuously evaluated against pharmacy accuracy benchmarks, with human-in-the-loop safeguards ensuring pharmacists retain final clinical authority.

For more information about CVS Health's technology and innovation initiatives, visit CVSHealth.com.

###

About CVS Health

CVS Health is a leading health solutions company simplifying health care one person, one family, and one community at a time. As of March 31, 2026, the Company had approximately 9,000 retail pharmacy locations, more than 1,000 walk-in and primary care medical clinics and a leading pharmacy benefits manager with approximately 88 million plan members. The Company also serves an estimated more than 37 million people through a broad range of health insurance products and related services. The Company's integrated model uses personalized, technology driven services to connect people to simply better health, increasing access to quality care, delivering better outcomes, and lowering overall costs.

Media contact

Tara Burke
646-765-4971
BurkeT1@CVSHealth.com

Find more stories and multimedia from CVS Health at 3blmedia.com.

Contact Info:
Spokesperson: CVS Health
Website: https://www.3blmedia.com/profiles/cvs-health
Email: info@3blmedia.com

SOURCE: CVS Health



View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/cvs-health-recognized-for-technology-that-improves-medication-safety-1174428

© 2026 ACCESS Newswire
SpaceX-Hype zu teuer – Diese 5 Aktien bieten bessere Chancen
Raumfahrt-Aktien gehören aktuell zu den heißesten Wetten an den Börsen. Spätestens mit dem spektakulären Börsengang von SpaceX ist der Sektor endgültig im Fokus der Anleger angekommen. Fantasien rund um Satellitenkommunikation, Rechenzentren im All und neue Geschäftsmodelle treiben die Kurse immer weiter nach oben.

Doch während die Begeisterung steigt, werden auch die Risiken größer. Viele Space-Start-ups sind inzwischen extrem hoch bewertet, arbeiten noch nicht profitabel und hängen stark von stetigem Kapitalzufluss ab. Schon kleine Rückschläge könnten die ambitionierten Wachstumspläne ins Wanken bringen.

Für Anleger, die vom Boom der Raumfahrt profitieren wollen, lohnt sich daher ein Perspektivwechsel. Statt auf überhitzte Pure Plays zu setzen, rücken etablierte Konzerne in den Fokus – Unternehmen mit jahrzehntelanger Erfahrung, stabilen Cashflows und engen Verbindungen zu Raumfahrtagenturen wie NASA und ESA.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau dieses Profil erfüllen: solide bewertet, operativ stark und bestens positioniert, um langfristig vom Space-Boom zu profitieren.

Jetzt den kostenlosen Report sichern – bevor der Markt die versteckten Gewinner entdeckt!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.